NAVB Oldtimers Lounge - Lymphoseek available in Germany (finally) - NAVB Oldtimers Lounge - InvestorVillage
NAVB Oldtimers Lounge
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: NAVB Oldtimers Lounge   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  16280 of 16310  at  9/12/2018 4:15:22 AM  by

wolfgang-germany


Lymphoseek available in Germany (finally)

i do not remind to read any launching-announcement by Norgine for launch in Germany, yet they now write:

---

LYMPHOSEEK®– a novel radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. LYMPHOSEEK® was launched in additional markets across Europe. It is available in Denmark, the Netherlands, the UK, GERMANY and Spain.

copied from here:

Norgine releases H1 2018 results


Strong performance in the first half of 2018 reflects the continued growth of Norgine’s leading brands as well as product revenues acquired through the acquisition of Merus Labs International Inc. (“Merus”)



Merus integration complete





AMSTERDAM, The Netherlands. 12 September 2018. 08:00 AM CST.



Norgine generated sales of €196 million in the first half of 2018 (H1 2018), 28% higher than in H1 2017. This growth was driven by the established products added by the acquisition of Merus (+ €32 million sales) and growth of Norgine’s key promoted products – particularly MOVICOL® and XIFAXAN® (+ €11million vs. H1 2017).



Norgine continues to drive performance of its products in Europe, Australia and New Zealand where it is investing for future growth.

MOVICOL®– the market leading treatment for constipation grew strongly year-on-year with sales of €79.0 million in H1 2018, up 6% from H1 2017



MOVIPREP®– Norgine’s 2 litre bowel preparation for colonoscopy – achieved sales of €29.8 million in H1 2018, up 5% from H1 2017



PLENVU®– the first 1 litre bowel preparation for colonoscopy received FDA approval in May 2018 and was launched in the US in September 2018. It is available through Norgine's infrastructure in Europe, Australia and New Zealand.



XIFAXAN® 550mg – for the treatment of hepatic encephalopathy – saw sales of €30 million in H1 2018, up 21% from H1 2017



LYMPHOSEEK®– a novel radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. LYMPHOSEEK® was launched in additional markets across Europe. It is available in Denmark, the Netherlands, the UK, Germany and Spain.









Significant key business developments

Following the acquisition of Merus in July 2017, the integration is now complete
Norgine continues its growth strategy and moved to a new office in Wettenberg, Germany. Germany is Norgine's largest market.



Peter Stein, CEO at Norgine said: “Our performance during the first half of 2018 demonstrates that our strategy is working. We are continuing to bring transformative products to market for the benefit of patients. The established products acquired through Merus and our promoted products, in particular MOVICOL® and XIFAXAN®, are key growth drivers for us. With the addition of PLENVU® to our product portfolio, we anticipate further growth in the remainder of 2018 and into 2019. Our success is a reflection of the hard work of our “One Norgine” team which has built a strong platform through which we can attract new opportunities for the benefit of patients.”

Ends


Notes to Editors:

About Norgine



Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.



Norgine is headquartered in the Netherlands.



For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 824
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
16281 Re: Lymphoseek available in Germany (finally) simple 0 9/12/2018 3:36:18 PM
16283 Re: Lymphoseek available in Germany (finally) wolfgang-germany 0 9/15/2018 11:13:44 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...